Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2009, 34(10): 793
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2009 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2009.034.10.1417872
Campas, C., Bolos, J., Castaner, R.
Abstract Tivozanib is a novel oral quinoline urea derivative with potent and selective activity against vascular endothelial growth factor (VEGFR) tyrosine kinase. Preclinical data indicate that tivozanib blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo. Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients. Early clinical trials demonstrated inhibition of angiogenesis and tumor progression in several types of advanced solid tumors. The compound is under early clinical investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences